前沿生物(688221) - 2021 Q3 - 季度财报

Financial Performance - The company's operating revenue for Q3 2021 was ¥11,833,950.46, a decrease of 27.74% compared to the same period last year[5]. - The net profit attributable to shareholders was -¥83,929,001.12, with a year-to-date net profit of -¥177,374,555.26[5]. - The company reported a basic earnings per share of -¥0.23 for the quarter, compared to -¥0.49 year-to-date[6]. - The weighted average return on equity was -4.24%, an increase of 6.95 percentage points compared to the previous year[6]. - The net loss for the first three quarters of 2021 was ¥182,588,009.18, compared to a net loss of ¥166,607,370.49 in the same period of 2020, indicating a worsening financial performance[26]. - The total comprehensive loss for the first three quarters of 2021 was ¥182,594,473.61, compared to a loss of ¥166,621,314.31 in the same period of 2020[26]. Research and Development - Research and development expenses totaled ¥53,147,864.40 for the quarter, representing 449.11% of operating revenue, an increase of 180.68 percentage points[6]. - The company invested a total of ¥109,174,771.42 in R&D from the beginning of the year to the end of the reporting period, an increase of 8.88% year-on-year[6]. - The company has invested ¥10,917.48 million in R&D from January to September 2021[13]. Assets and Liabilities - Total assets at the end of the reporting period were ¥2,465,528,798.73, a decrease of 2.02% from the end of the previous year[6]. - As of September 30, 2021, total current assets amounted to RMB 1,617,177,882.96, a decrease from RMB 1,848,172,697.84 as of December 31, 2020[22]. - The company reported a total liability of RMB 542,746,079.15 as of September 30, 2021, an increase from RMB 375,669,442.36 at the end of 2020[23]. - The company's total assets as of September 30, 2021, were RMB 2,465,528,798.73, compared to RMB 2,516,290,135.69 at the end of 2020[24]. - The company’s cash and cash equivalents as of September 30, 2021, were RMB 287,558,111.69, down from RMB 839,094,950.34 at the end of 2020[21]. - The company’s inventory as of September 30, 2021, was RMB 14,474,885.22, slightly up from RMB 13,529,745.60 at the end of 2020[21]. Cash Flow - The company recorded a net cash flow from operating activities of -¥157,320,954.47 year-to-date[5]. - Cash flow from operating activities showed a net outflow of ¥157,320,954.47 in 2021, compared to a net outflow of ¥114,618,845.70 in 2020, reflecting increased operational challenges[28]. - Investment activities resulted in a net cash outflow of ¥523,592,532.76 in 2021, compared to a smaller outflow of ¥13,282,942.16 in 2020, indicating significant investment expenditures[29]. - Cash and cash equivalents at the end of Q3 2021 totaled ¥287,558,111.69, down from ¥839,094,950.34 at the beginning of the year, showing a decrease in liquidity[29]. Clinical Trials and Product Development - The company is conducting multiple clinical trials for its pipeline products, including FB1002 and FB2001, with various stages of participant enrollment and safety evaluations ongoing in the U.S. and China[15]. - The company has received a notice from the National Medical Products Administration regarding the acceptance of a clinical trial supplement application for intravenous administration of Aikening, which will enhance clinical usability and compliance once approved[14]. - The storage conditions for the product Aikening have been approved to change from "light-proof, sealed, frozen" to "light-proof, sealed, refrigerated," which reduces transportation and storage requirements for distributors and hospitals, facilitating market promotion and lowering delivery costs[14]. Equity and Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 15,769[10]. - The company's equity attributable to shareholders was approximately $2.14 billion, with a decrease in undistributed profits of approximately $809.31 million[33].